Back to News
Market Impact: 0.55
Ultragenyx's rare disease drug fails in late-stage trial; shares plunge
Source: reuters.com
Healthcare & BiotechCompany FundamentalsAnalyst InsightsCorporate Guidance & Outlook
Ultragenyx reported its experimental drug for a rare genetic neurodevelopmental disorder missed the primary endpoint in a late-stage trial. Shares fell 40% in aftermarket trading, signaling major execution risk despite the continued development uncertainty.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
RARE-0.90
More News
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Choosing an AI Copilot for Equity Research
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience